Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

A Phase 1 Trial Evaluating the Addition of Lenalidomide to Relapsed/Refractory Multiple Myeloma Patients Progressing on Ruxolitinib and Methylprednisolone

James R Berenson, Andrea Limon, Stephanie Rice, Tahmineh Safaie, Ralph Boccia, Honghao Yang, Mehdi M. Moezi, Stephen Lim, Gary Schwartz, Shahrooz Eshaghian, Matthew Brobeck, Regina Swift, Benjamin M. Eades, Sean Bujarski, Yohana Sebhat, Rudra Ray, Susanna Kim, Robert Allen Vescio

Blood (2023) 142 (Supplement 1): 4753.

https://doi.org/10.1182/blood-2023-180287

Published: 2023

Journal Articles

Outcomes of Triple Class Refractory Multiple Myeloma Patients: A Single Center Retrospective Study

Ryan Danis, David Yashar, Sean Bujarski, Scott Jew, Regina Swift, James R Berenson

Blood (2023) 142 (Supplement 1): 3369.

https://doi.org/10.1182/blood-2023-187318

Published: 2023

Journal Articles

Ruxolitinib and Methylprednisolone for Treatment of Patients with Relapsed/Refractory Multiple Myeloma

James R. Berenson, Daisy Martinez, Tahmineh Safaie, Ralph Boccia, Honghao H Yang, Mehdi M. Moezi, Stephen Lim, Gary Edward Schwartz, Shahrooz Eshaghian, Regina Swift, Benjamin Eades, Sean Elliott Bujarski, Bernard Sean Regidor, Clara Kim, Susanna Kim, Robert Vescio

Blood (2022) 140 (Supplement 1): 12610–12611.

https://doi.org/10.1182/blood-2022-163872

Published: 2022

Journal Articles

Sars-Cov-2 Antibody Decay Monitoring in mRNA Vaccinated Multiple Myeloma Patients

Samuel D. Stampfer, Marissa-Skye Goldwater, Bernard Sean S. Regidor, Scott Kristian Jew, Sean Elliott Bujarski, Haiming Chen, David Yashar, Ning Xu, Mingjie Li, Tracy Green, Eddie Fung, Elias Aquino, Regina Swift, Shahrooz Eshaghian, Aaron Feinstein, James R. Berenson

Blood (2021) 138 (Supplement 1): 2712.

https://doi.org/10.1182/blood-2021-154287

Published: 2021

Journal Articles

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma

James R. Berenson, Daisy Martinez, Tahmineh Safaie, Noemi Silagan, Jennifer To, Tanya M. Spektor, Eli Forouzan, Regina Swift, Benjamin Eades, Shahrooz Eshaghian, Gary Schwartz, Ralph V. Boccia, Honghao H Yang, Mehdi M. Moezi, Stephen Lim, Robert Vescio

Blood (2021) 138 (Supplement 1): 2727.

https://doi.org/10.1182/blood-2021-151016

Published: 2021

Journal Articles

Retrospective Analysis of Response Rates to Anti-CD38 Monoclonal Antibody Containing Regimens Among Multiple Myeloma Patients with Prior Exposure to Daratumumab or Isatuximab

David Yashar, Bernard Sean S. Regidor, Scott Kristian Jew, Sean Bujarski, Marissa-Skye Goldwater, Regina Swift, Gary Edward Schwartz, Shahrooz Eshaghian, Robert Vescio, James R. Berenson

Blood (2021) 138 (Supplement 1): 3785.

https://doi.org/10.1182/blood-2021-154350

Published: 2021

Journal Articles

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

James R. Berenson, MD, Noemi Silagan, MD, Jennifer To, BS, Tanya M. Spektor, PhD, Daisy Martinez, Armando J. Sanchez, Eli Forouzan, Regina Swift, Benjamin Eades, PharmD, Gary Schwartz, MD, Shahrooz Eshaghian, MD, Ralph V. Boccia, MD, Honghao Hank Yang, Stephen Lim, MD, Robert Vescio, MD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-143005

Published: 2020

Journal Articles

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

James R. Berenson, MD, Jennifer To, BS, Tanya M. Spektor, PhD, Daisy Martinez, Armando J. Sanchez, MBA, Carley Turner, CCRP, Regina Swift, Benjamin Eades, PharmD, Gary Schwartz, MD, Shahrooz Eshaghian, MD, Laura V. Stampleman, Robert A. Moss, MD, Youram Nassir, MD, Ravindranath Patel, MD, Alberto Bessudo, MD, Daniel Greenwald, MD, Ralph V. Boccia, MD, Stephen Lim, MD, Robert Vescio, MD

Blood (2019) 134 (Supplement_1): 1903.

https://doi.org/10.1182/blood-2019-131370

Published: 2019

Journal Articles

Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments

Sean Bujarski, BA, Kyle Udd, BA, Camilia Soof, BS, Tanya M. Spektor, PhD, Tahmineh Safaie, Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Joshua Stern, Cathy S. Wang, BS, Ning Xu, PhD, Marsiye Emamy-Sadr, Regina Swift, Ashkon Rahbari, Saurabh Patil, BS, Eric Souther, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 1786.

https://doi.org/10.1182/blood-2019-132012

Published: 2019

Journal Articles

Normalization of Serum B-Cell Maturation Antigen Levels from Treatment Predicts Progression Free and Overall Survival in Multiple Myeloma Patients

Scott Kristian Jew, BS, Tiffany Chang, BS, Sean Elliott Bujarski, BA, Camilia Soof, BS, Haiming Chen, MD PhD, Tahmineh Safaie, Mingjie Li, BS, Eric Sanchez, BA, Cathy S. Wang, BS, Marsiye Emamy-Sadr, Regina Swift, Ashkon Rahbari, Saurabh Patil, BS, Eric Souther, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 4393.

https://doi.org/10.1182/blood-2019-132013

Published: 2019

Journal Articles

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Relapsed/Refractory Multiple Myeloma Patients

James R Berenson, MD, To Jennifer, BS, Tanya M. Spektor, PhD, Carley Turner, CCRP, Regina Swift, Benjamin Eades, PharmD, Gary Schwartz, MD, Shahrooz Eshaghian, MD, Laura V. Stampleman, Robert A. Moss, MD, Alberto Bessudo, MD, Ravindranath Patel, MD, Stephen Lim, MD, Robert Vescio, MD

Blood (2018) 132 (Supplement 1): 1988.

https://doi.org/10.1182/blood-2018-99-119274

Published: 2018

Journal Articles

Baseline and Early Changes in Serum B-Cell Maturation Antigen Levels Predict Progression Free Survival and Response Status for Multiple Myeloma Patients in a Phase 1 Trial Evaluating Ruxolitinib, Lenalidomide and Methylprednisolone

Sean Bujarski, BA, Camilia Soof, BS, Mingjie Li, BS, Cathy S. Wang, BS, Eric Sanchez, BA, Marsiye Emamy-Sadr, Regina Swift, Kian Rahbari, Saurabh Patil, BS, Tanya M. Spektor, PhD, Haiming Chen, MD PhD, James R. Berenson, MD

Blood (2018) 132 (Supplement 1): 1894.

https://doi.org/10.1182/blood-2018-99-119190

Published: 2018

Journal Articles

Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Multiple Myeloma Patients Undergoing New Treatments

Sean Bujarski, BA, Kyle Udd, BA, Camilia Soof, BS, Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Joshua Stern, Cathy S Wang, BS, Marsiye Emamy-Sadr, Regina Swift, Ashkon Rahbari, Saurabh Patil, BS, James R Berenson, MD

Blood (2017) 130 (Supplement 1): 4371.

https://doi.org/10.1182/blood.V130.Suppl_1.4371.4371

Published: 2017

Journal Articles

Efficacy and Safety of Pomalidomide As a Replacement Therapy for Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients Refractory to a Lenalidomide-Containing Combination Regimen

James R Berenson, MD, Alexa Cohen, Tanya M. Spektor, PhD, Ashkan Lashkari, MD, Roy Mackintosh, MD, Alberto Bessudo, MD, Haresh Jhangiani, Nashat Gabrail, MD, Ibrahim Nakhoul, MD, Samir Kubba, MD, Jeffrey D. Neidhart, MD BS, Maluso Tina, Regina Swift, Robert Vescio, MD

Blood (2017) 130 (Supplement 1): 3106.

https://doi.org/10.1182/blood.V130.Suppl_1.3106.3106

Published: 2017

Journal Articles

Changes in Serum B-Cell Maturation Antigen Levels Are a More Rapid Indicator of Therapeutic Response or Disease Progression for Patients with Multiple Myeloma

Kyle Udd, BA, Haiming Chen, MD PhD, Mingjie Li, BS, Camilia M Soof, BS, Christian Casas, BS, Soudabeh Etessami, PhD, Zachary Gross, MD, Matthew Ghermezi, James Wang, Eric Sanchez, BA, Cathy S Wang, BS, Marsiye Emamy-Sadr, Regina Swift, RN, James R. Berenson, MD

Blood (2016) 128 (22): 5654.

https://doi.org/10.1182/blood.V128.22.5654.5654

Published: 2016

Journal Articles

Serum CD147 Levels Are Increased in Multiple Myeloma Patients and Elevated Levels Are Associated with Refractory Disease and Shortened Progression Free Survival

Zachary Gross, MD, Kyle Udd, BA, Matthew Ghermezi, Soudabeh Etessami, PhD, Haiming Chen, MD PhD, Tanya M. Spektor, PhD, Mingjie Li, BS, George Tang, PhD, Cathy S Wang, BS, Eric Sanchez, BA, Camilia M Soof, BS, Christian E Casas, BS, Regina Swift, RN, James R. Berenson, MD

Blood (2016) 128 (22): 5652.

https://doi.org/10.1182/blood.V128.22.5652.5652

Published: 2016

Journal Articles

Results from the Phase I Portion of a Phase I/II Study of ATN-224 and Bortezomib for Patients with Multiple Myeloma Relapsed from or Refractory to Bortezomib

James R. Berenson, MD, Thomas Ervin, MD, Ralph V. Boccia, MD, Olcay Batuman, MD, Regina Swift, RN, Christina DiLauro Abaya, BA, Andrew P. Mazar, PhD, Gilad S. Gordon, MD, Steven D. Reich, MD, Jennifer A. Callahan, BA

Blood (2008) 112 (11): 5185.

https://doi.org/10.1182/blood.V112.11.5185.5185

Published: 2008

Journal Articles

A Phase I/II Trial Evaluating the Combination of Arsenic Trioxide, Bortezomib and Ascorbic Acid for Patients with Relapsed or Refractory Multiple Myeloma.

James Berenson, Jeff Matous, Delina Ferretti, Regina Swift, Russell Mapes, Blake Morrison, Howard Yeh, Sal Bevivino

Blood (2005) 106 (11): 2565.

https://doi.org/10.1182/blood.V106.11.2565.2565

Published: 2005

NARROW

A Phase 1 Trial Evaluating the Addition of Lenalidomide to Relapsed/Refractory Multiple Myeloma Patients Progressing on Ruxolitinib and Methylprednisolone

Outcomes of Triple Class Refractory Multiple Myeloma Patients: A Single Center Retrospective Study

Ruxolitinib and Methylprednisolone for Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Sars-Cov-2 Antibody Decay Monitoring in mRNA Vaccinated Multiple Myeloma Patients

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma

Retrospective Analysis of Response Rates to Anti-CD38 Monoclonal Antibody Containing Regimens Among Multiple Myeloma Patients with Prior Exposure to Daratumumab or Isatuximab

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments

Normalization of Serum B-Cell Maturation Antigen Levels from Treatment Predicts Progression Free and Overall Survival in Multiple Myeloma Patients

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Relapsed/Refractory Multiple Myeloma Patients

Baseline and Early Changes in Serum B-Cell Maturation Antigen Levels Predict Progression Free Survival and Response Status for Multiple Myeloma Patients in a Phase 1 Trial Evaluating Ruxolitinib, Lenalidomide and Methylprednisolone

Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Multiple Myeloma Patients Undergoing New Treatments

Efficacy and Safety of Pomalidomide As a Replacement Therapy for Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients Refractory to a Lenalidomide-Containing Combination Regimen

Changes in Serum B-Cell Maturation Antigen Levels Are a More Rapid Indicator of Therapeutic Response or Disease Progression for Patients with Multiple Myeloma

Serum CD147 Levels Are Increased in Multiple Myeloma Patients and Elevated Levels Are Associated with Refractory Disease and Shortened Progression Free Survival

Results from the Phase I Portion of a Phase I/II Study of ATN-224 and Bortezomib for Patients with Multiple Myeloma Relapsed from or Refractory to Bortezomib

A Phase I/II Trial Evaluating the Combination of Arsenic Trioxide, Bortezomib and Ascorbic Acid for Patients with Relapsed or Refractory Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only